West Pharmaceutical Services, Inc. (NYSE: WST) provides injectable drug administration solutions and services for pharmaceutical, biotechnology and generic drug customers. Its business includes elastomer-based packaging components such as stoppers, seals and plungers, nonglass containment technologies, auto-injectors and contract services for device manufacturing, assembly, packaging, validation, analytical testing and regulatory support.
News about West commonly covers quarterly results, revenue guidance, Proprietary Products and Contract Manufacturing performance, capacity additions for high-volume injectable therapies, and demand tied to biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. Other recurring developments include dividends, share repurchase authorizations, investor conference participation and governance or executive-transition updates.
West Pharmaceutical Services (NYSE: WST) will present at the Jefferies Global Healthcare Conference in London on November 18, 2026. The presentation is scheduled for 8:00 a.m. GMT. A live audio webcast will be available through the Investors section of the company website, with a replay available for approximately 90 days after the event.
West Pharmaceutical Services (NYSE: WST) reported third-quarter 2026 net sales of $874.5 million and raised its full-year sales and adjusted earnings outlook. Sales rose 8.7% year over year, with organic growth of 11.9%. Diluted earnings per share increased 57.3% to $3.02; adjusted diluted earnings per share rose 35.7% to $2.66.
Proprietary Products sales increased 12.6% to $728.8 million, while West Vantage sales declined 7.3% to $145.7 million. Gross margin expanded to 39.7% from 36.6%. West now expects full-year sales of $3.41 billion to $3.42 billion and adjusted diluted earnings per share of $9.38 to $9.48. Capital spending guidance fell to $215 million to $220 million. Quarterly share repurchases totaled $231 million, and the fourth-quarter dividend increased 18% to $0.26 per share. Year-to-date operating cash flow was $403 million.
West Pharmaceutical Services (NYSE: WST) declared a fourth-quarter common-stock dividend of $0.26 per share, payable on November 18, 2026.
The dividend is an 18% increase over the prior quarter's $0.22 per share and marks the company's thirty-fourth consecutive annual dividend increase. Shareholders of record on November 11, 2026, will receive the payment.
West Pharmaceutical Services (WST) will release third-quarter 2026 financial results before the market opens on October 29, 2026. A conference call discussing the results and business expectations will follow at 8:00 a.m. Eastern Time. A slide presentation will be available that day in the website’s Investors section, and a webcast replay will remain available for approximately 90 days.
West Pharmaceutical Services (WST) announced its participation in CPHI Worldwide in Milan, Italy, to present drug packaging and delivery technologies. West will showcase its SelfDose patient-controlled injector, powered by the West Synchrony S1 prefillable syringe system. Richard Kieran will present on drug-device development partnerships on October 6, and Dan Yates will join a panel on large-volume drug delivery on October 7.
West Pharmaceutical Services (NYSE: WST) will present at two investor conferences in September 2026. The company is scheduled for the Wells Fargo Annual Healthcare Conference on Thursday, September 10, 2026 at 8:45 a.m. EDT in Everett, MA, and the Morgan Stanley Annual Global Healthcare Conference on Monday, September 14, 2026 at 8:30 a.m. EDT in New York, NY. Live webcasts and 90-day replays for both events will be available in the Investors section of the company’s website.
West Pharmaceutical Services (NYSE: WST) reported second-quarter 2026 net sales of $872.3 million, up 13.8% year over year, with 12.7% organic growth. Diluted EPS was $2.15, up 18.1%, and adjusted-diluted EPS reached $2.37, up 28.8%. Operating profit rose to $179.1 million, with a 20.5% margin, while adjusted operating margin improved to 22.6% from 20.3%.
Free cash flow was $128.0 million on operating cash flow of $213.9 million and capital expenditures of $85.9 million. The company repurchased 1.8 million shares for $454.3 million in the first half of 2026 and declared a third-quarter dividend of $0.22 per share.
Proprietary Products segment net sales grew 16.6% to $722.6 million, led by High-Value Product Components and Delivery Devices, while West Vantage net sales increased 2.0% to $149.7 million.
West raised its full-year 2026 net sales guidance to $3.345–$3.380 billion and increased adjusted-diluted EPS guidance to $8.85–$9.05. Third-quarter 2026 net sales are guided to $820–$835 million and adjusted EPS to $2.14–$2.24.
West Pharmaceutical Services (NYSE: WST) announced that its Board of Directors declared a regular quarterly dividend of $0.22 per share on its common stock on July 21, 2026. The dividend will be paid on August 5, 2026 to shareholders of record as of July 29, 2026.
West (NYSE:WST) will release its second-quarter 2026 financial results before the market opens on Thursday, July 23, 2026, followed by a conference call at 8:00 a.m. Eastern Time. A live webcast, slide presentation, and 90-day replay will be available on the investor website.
West (NYSE: WST) completed the sale and transfer of the manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System and associated facilities. The transaction closed on July 1, 2026. West will continue developing and manufacturing other SmartDose versions, including the SmartDose 10mL On-Body Delivery System.